Oragenics Reports Q2 2025 Financial Results with $2.3 Million Net Loss

Oragenics, Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $2.3 million for the three months ended June 30, 2025, a slight improvement from a net loss of $2.3 million in the same period of 2024. For the six months ending June 30, 2025, the company recorded a net loss of $4.5 million, compared to a loss of $4.8 million in the prior year. The company did not generate any revenue during either period. Total operating expenses decreased by 25.7% to $1.7 million for the second quarter and by 21.5% to $3.7 million for the first half of 2025, primarily due to reduced research and development costs.

The company’s cash and cash equivalents increased significantly to $2 million as of June 30, 2025, up from $864,840 at the end of 2024. This increase was attributed to financing activities, including net proceeds of approximately $2.6 million from the issuance of common stock and $2.2 million from a promissory note. However, total liabilities rose to $4.3 million, driven by the issuance of the $3 million promissory note, which was repaid in full on July 2, 2025, using proceeds from a public offering of Series H Preferred Stock.

Oragenics has focused its efforts on advancing its lead product candidate, ONP-002, which is intended for the treatment of mild traumatic brain injury. The company is preparing to initiate a Phase IIa clinical trial in Australia and New Zealand, with expectations to start in the third quarter of 2025. The decrease in research and development expenses in 2025 was primarily due to a shift in focus solely to ONP-002, as previous periods included costs related to other programs that are no longer active.

In terms of organizational changes, Janet Huffman was appointed as the Chief Executive Officer on May 2, 2025, while continuing her role as Chief Financial Officer. The company also executed a 1-for-30 reverse stock split on June 3, 2025, which adjusted the number of shares outstanding. As of June 30, 2025, Oragenics had 822,927 shares of common stock issued and outstanding, reflecting the impact of the reverse split.

Looking ahead, Oragenics anticipates continued operating losses as it advances ONP-002 through clinical trials and regulatory processes. The company has indicated that its current cash position, bolstered by the recent public offering, is expected to support operations through the first half of 2026. However, substantial doubt remains regarding its ability to continue as a going concern without securing additional capital to fund operations beyond this period.